Project Grant R43AI140817

This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), focuses on developing novel, non-invasive diagnostic and prognostic biomarkers for invasive aspergillosis (IA) in immunocompromised patients. The $181,861 award, effective from December 2, 2024 to November 30, 2029, will enable the awardee, Duke University, to: Derive and optimize a diagnostic host gene expression...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $199,584 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Albert Einstein College of Medicine. The grant will fund a 5-year research project led by Dr. Hyun Ah Yoon to identify antibody biomarkers that can predict the risk of cryptococcosis in immunosuppressed solid organ transplant recipients. The study will retrospectively analyze changes in plasma immunoglobulin levels and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 in funding to Microrid Technologies Inc. to discover and develop new antifungal therapeutics. The goal is to identify inhibitors of the fungal enzyme ceramide synthase 1 (CER1), which is essential for fungal growth in various host environments. The project will screen chemical libraries to find potent and...

This $870,800 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development and validation of a high-throughput screening assay to identify novel, mold-active antifungal compounds. The University of Iowa, the award recipient, will utilize this luciferase-based screening platform to conduct a large-scale evaluation of a synthetic compound library for activity against the fungal pathogen...

This $700,000 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the clinical validation of Prenosis, Inc.'s "Immunix" precision medicine platform for acute care conditions like sepsis. The Immunix platform combines clinical data, novel biomarker assays, and AI-enabled analytics to classify patients into distinct "endotypes" based on their underlying biological...

This Project Grant award of $558,747, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate a novel link between the fungal virulence factor calcineurin, amino acid permease, and protein kinase A in the pathogen Mucor that causes the life-threatening infection mucormycosis. The research aims to identify key transcription factors regulated by calcineurin, elucidate the...

This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel electrochemical lateral flow assay (ELFA) for diagnosing active tuberculosis (TB) from a single drop of blood. The $238,500 award will enable the University of California, San Diego (UCSD) to determine the operating characteristics of the ELFA using contrived samples and bio-banked...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to evaluate safer and more effective antifungal strategies for treating talaromycosis, a deadly fungal infection prevalent in Southeast Asia. The $1,326,630 award will fund a clinical trial to test whether a single high-dose of liposomal amphotericin B (LAMB) is superior to the standard 14-day course of...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,208,700 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, San Diego (UCSD). The grant aims to develop a novel, rapid, and accurate diagnostic test for detecting active tuberculosis (TB) disease, particularly in people living with HIV. The key products and services to be delivered through this grant include: Determining the analytical performance...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $642,775 to the University of California, Davis (UC Davis) to accelerate the discovery of novel antifungal peptides using one-bead one-compound (OBOC) combinatorial technology. The research aims to develop a high-throughput screening platform to identify membrane-active antifungal peptides that can effectively...